Selective down-regulation of Th2 immune responses following treatment with antigen-coupled splenocytes.
Intravenous injection of antigen-coupled splenocytes has been widely used to induce specific tolerance to a variety of antigens. In this study, we investigated the effects of such a treatment on Th1 and Th2 antigen-specific immune responses. Using both well-characterized model antigens and crude homogenates from Leishmania major promastigotes, we found that intravenous injection of antigen-coupled splenocytes strongly down-regulated antigen-specific Th2 responses but had no or only moderate effects on Th1 responses. Because the susceptibility of inbred strains of mice to murine leishmaniasis has been found to be correlated with a strong Th2 response against parasite antigens, we investigated whether administration of splenocytes chemically coupled to parasite antigens could protect susceptible mice from murine leishmaniasis. We found that this was indeed the case and further demonstrated that protection was associated with a strong decrease in the number of parasite-specific Th2-like cells. Because administration of antigen-coupled splenocytes is believed to induce ligation of the T cell receptor complex without inducing a co-stimulatory signal, our results further suggest that priming of Th1 cells is less dependent on co-stimulatory signals than the priming of Th2 cells.
Soldera
S
S
Centre National de la Recherche Scientifique, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France.
McSorley
S J
SJ
Glaichenhaus
N
N
D019264:Adoptive Transfer; D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000494:pharmacology*; D000953:Antigens, Protozoan / Q000008:administration & dosage / Q000276:immunology; D015536:Down-Regulation / Q000276:immunology*; D005260:Female; D007113:Immunity, Innate; D007275:Injections, Intravenous; D018320:Leishmania major / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D016773:Leishmaniasis, Cutaneous / Q000276:immunology / Q000517:prevention & control; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology; D011485:Protein Binding / Q000276:immunology; D015800:Protozoan Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000469:parasitology / Q000637:transplantation*; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism
D000941:Antigens; D000953:Antigens, Protozoan; D008222:Lymphokines; D015800:Protozoan Proteins; C093139:LACK antigen, Leishmania; D010047:Ovalbumin